JPH10510996A - ヒト好中球エラスターゼ阻害特別設計ヒト由来クニッツドメイン - Google Patents
ヒト好中球エラスターゼ阻害特別設計ヒト由来クニッツドメインInfo
- Publication number
- JPH10510996A JPH10510996A JP8520491A JP52049196A JPH10510996A JP H10510996 A JPH10510996 A JP H10510996A JP 8520491 A JP8520491 A JP 8520491A JP 52049196 A JP52049196 A JP 52049196A JP H10510996 A JPH10510996 A JP H10510996A
- Authority
- JP
- Japan
- Prior art keywords
- dpi
- hne
- protein
- epi
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8114—Kunitz type inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Insects & Arthropods (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Analytical Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.50ピコモル未満のKi でhNEに結合し阻害する、遺伝子操作されたア プロチニン様クニッツドメインを包含する非天然起源タンパク質であって、 前記ドメインは配列EPI-HNE-3、EPI-HNE-4、DPI.1.1、DPI.1.2、DPI.1.3、DPI .2.1、DPI.2.2、DPI.2.3、DPI.3.1、DPI.3.2、DPI.3.3、DPI.4.1、DPI.4.2、DPI .4.3、DPI.5.1、DPI.5.2、DPI.5.3、DPI.6.1、DPI.6.2、DPI.6.3、DPI.6.4、DPI .6.5、DPI.6.6、DPI.6.7、DPI.7.1、DPI.7.2、DPI.7.3、DPI.7.4、DPI.7.5、DPI .8.1、DPI.8.2、DPI.8.3、DPI.9.1、DPI.9.2およびDPI.9.3からなる群より選ば れた参照配列と、最初のシステインから最後のシステインまで伸びる相同領域に わたって、実質的に相同であるアミノ酸配列を包含し、 前記ドメインは EpiNEalpha、EpiNE1、EpiNE2、EpiNE3、EpiNE4、EpiNE5、Epi NE6、EpiNE7、EpiNE8、ITI-E7、BITI-E7、BITI-E7-1222、AMINO1、AMINO2、MUTP 1、BITI-E7-141、MUTT26A、MUTQE、およびMUT1619ドメインからなる群から選ば れたどのドメインとも同一でない、非天然起源タンパク質。 2.前記領域中で、前記ドメインは参照配列と少なくとも80%同一であり、 前記参照タンパク質配列とは、違っているとしても一つかそれ以上の保存性変異 で異なっているにすぎない、請求の範囲第1項に記載のタンパク質。 3.前記ドメインが配列EPI-HNE-3、EPI-HNE-4、DPI.1.1、DPI.1.2、DPI.1.3 、DPI.2.1、DPI.2.2、DPI.2.3、DPI.3.1、DPI.3.2、DPI.3.3、DPI.4.1、DPI.4.2 、DPI.4.3、DPI.5.1、DPI.5.2、DPI.5.3、DPI.6.1、DPI.6.2、DPI.6.3、DPI.6.4 、DPI.6.5、DPI.6.6、DPI.6.7、DPI.7.1、DPI.7.2、DPI.7.3、DPI.7.4、DPI.7.5 、DPI.8.1、DPI.8.2、DPI.8.3、DPI.9.1、DPI.9.2およびDPI.9.3からなる群から 選ばれる配列と同一であるアミノ酸配列を包含する、請求の範囲第2項に記載の タンパク質。 4.前記ドメインが天然起源アプロチニン型クニッツドメインとは、少なくと も突然変異X18Fと、X15VおよびX15Iからなる群から選ばれた突然変異で異なる、 請求の範囲第1項に記載のタンパク質。 5.前記ドメインが天然起源アプロチニン型クニッツドメインとは、[X16A、 X16G];[X17F、X17L、X17I、X17M];[X19P、X19Q、X19K、X19S];X13P;[ X34V、X34P];[X39Q、X39M];[X32T、X32L];[X31Q、X31E、X31V];[X1 1T、X11A、X11R];[X10Y、X10S、X10V];[X40G、X40A];X36G;X37Gおよび X12Gからなる群から選ばれた少なくとも一つの変異で異なる、請求の範囲第4項 に記載のタンパク質。 6.最初のシステインから最後のシステインまで伸びる相同領域内で、遺伝子 操作されたドメインと、最も類似した天然起源アプロチニン様クニッツドメイン との間のアミノ酸配列の数の差が4個以下である、請求の範囲第1項に記載のタ ンパク質。 7.前記ドメインが配列EPI-HNE-3とEPI-HNE-4からなる群から選ばれるアミノ 酸配列を包含する、請求の範囲第1項に記載のタンパク質。 8.請求の範囲第1〜7項のいずれかに記載のタンパク質をコードするDNA 配列を包含するDNA分子。 9.請求の範囲第1〜7項のいずれかに記載のタンパク質をコードするDNA コード配列を包含する発現ベクターであって、前記コード配列は機能するよう制 御DNA配列に連結されており、それにより前記コード配列が前記タンパク質を 生産するために適切なホスト中で発現される発現ベクター。 10.請求の範囲第9項に記載の発現ベクターを包含する形質転換細胞であっ て、前記細胞は前記コード配列の発現に連結する条件下、前記調節配列の制御下 で前記タンパク質を生産する形質転換細胞。 11.前記コード配列の発現に連結する条件下で請求の範囲第10項に記載の 形質転換細胞を培養し、それにより前記タンパク質を前記細胞により生産するこ とを包含する、hNE阻害活性を有するタンパク質の製造方法。 12.細胞がピチア・パストリス(Pichia pastoris)の細胞である、請求の 範囲第11項に記載の方法。 13.ある場所においてhNE活性を阻害する方法であって、請求の範囲第1 項に記載のタンパク質の阻害量をその場所に導入することを包含する阻害方法。 14.その場所が動物中で過剰hNE活性を有する部位である請求の範囲13 項に記載の方法。 15.その動物がヒトである請求の範囲第14項に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/358,160 US5663143A (en) | 1988-09-02 | 1994-12-16 | Engineered human-derived kunitz domains that inhibit human neutrophil elastase |
US08/358,160 | 1994-12-16 | ||
PCT/US1995/016349 WO1996020278A2 (en) | 1994-12-16 | 1995-12-15 | Genetically engineered human-derived kunitz domains that inhibit human neutrophil elastase |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10510996A true JPH10510996A (ja) | 1998-10-27 |
JP3977419B2 JP3977419B2 (ja) | 2007-09-19 |
Family
ID=23408531
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52049196A Expired - Lifetime JP3977419B2 (ja) | 1994-12-16 | 1995-12-15 | ヒト好中球エラスターゼ阻害特別設計ヒト由来クニッツドメイン |
Country Status (9)
Country | Link |
---|---|
US (1) | US5663143A (ja) |
EP (2) | EP1734121A3 (ja) |
JP (1) | JP3977419B2 (ja) |
AT (1) | ATE311452T1 (ja) |
CA (1) | CA2207820A1 (ja) |
DE (1) | DE69534656T2 (ja) |
DK (1) | DK0797666T3 (ja) |
ES (1) | ES2255066T3 (ja) |
WO (1) | WO1996020278A2 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005538932A (ja) * | 2002-02-07 | 2005-12-22 | アベンティス、ベーリング、ゲゼルシャフト、ミット、ベシュレンクテル、ハフツング | アルブミン融合クニッツドメインペプチド |
JP2010254708A (ja) * | 2003-08-29 | 2010-11-11 | Dyax Corp | ポリペグ化されたプロテアーゼインヒビター |
US9480733B2 (en) | 2002-06-07 | 2016-11-01 | Dyax Corp. | Prevention and reduction of blood loss |
US9757437B2 (en) | 2004-09-27 | 2017-09-12 | Dyax Corp. | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
US10428158B2 (en) | 2014-03-27 | 2019-10-01 | Dyax Corp. | Compositions and methods for treatment of diabetic macular edema |
Families Citing this family (162)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7078383B2 (en) * | 1988-09-02 | 2006-07-18 | Dyax Corp. | ITI-D1 Kunitz domain mutants as HNE inhibitors |
US20060134087A1 (en) * | 1988-09-02 | 2006-06-22 | Dyax Corp. | ITI-D1 Kunitz domain mutants as hNE inhibitors |
DK0564531T3 (da) * | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
DE69533544T2 (de) * | 1994-01-11 | 2006-02-23 | Dyax Corp., Cambridge | Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten |
US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
US20060078561A1 (en) * | 1994-01-31 | 2006-04-13 | The Trustees Of Boston University | Polyclonal antibody libraries |
AU1736495A (en) | 1994-01-31 | 1995-08-15 | Trustees Of Boston University | Polyclonal antibody libraries |
US6010861A (en) * | 1994-08-03 | 2000-01-04 | Dgi Biotechnologies, Llc | Target specific screens and their use for discovering small organic molecular pharmacophores |
US5780265A (en) * | 1995-06-05 | 1998-07-14 | Genentech, Inc. | Kunitz type plasma kallikrein inhibitors |
US5786328A (en) * | 1995-06-05 | 1998-07-28 | Genentech, Inc. | Use of kunitz type plasma kallikrein inhibitors |
US6242414B1 (en) * | 1995-06-07 | 2001-06-05 | Chiron Corporation | Regulation of cytokine synthesis and release |
US20030199450A1 (en) * | 2001-04-27 | 2003-10-23 | Chiron Corporation | Regulation of cytokine synthesis and release |
YU8997A (sh) * | 1996-03-11 | 1999-09-27 | Bayer Corporation | Prečišćen protein koji ima serinsku proteaznu inhibitorsku aktivnost i farmaceutski preparat koji ga sadrži |
US5876925A (en) * | 1996-10-11 | 1999-03-02 | The Trustees Of The University Of Pennsylvania | Magnetically activated cell sorting for production of proteins |
US5985543A (en) * | 1996-10-11 | 1999-11-16 | The Trustees Of The University Of Pennsylvania | Compositions and methods for detection of antibody binding to cells |
US6262233B1 (en) | 1997-01-31 | 2001-07-17 | Human Genome Sciences, Inc. | Tissue factor pathway inhibitor-3 |
WO1999055365A1 (en) | 1998-04-30 | 1999-11-04 | Cornell Research Foundation, Inc. | Adenoviral vectors with tandem fiber proteins |
CA2330191A1 (en) * | 1998-06-03 | 1999-12-09 | Scios, Inc. | Protease inhibitor peptides |
CA2334170A1 (en) | 1998-07-27 | 2000-02-10 | Genentech, Inc. | Improved transformation efficiency in phage display through modification of a coat protein |
CA2342396A1 (en) | 1998-09-11 | 2000-03-23 | Genvec, Inc. | Alternatively targeted adenovirus |
US20070140979A1 (en) * | 1998-12-22 | 2007-06-21 | Bayer Aktiengesellschaft | Method for accelerating the rate of mucociliary clearance |
CN1229138C (zh) * | 1998-12-22 | 2005-11-30 | 拜尔公开股份有限公司 | 加速粘液纤毛的清除速率的方法 |
US6294648B1 (en) * | 1999-07-20 | 2001-09-25 | Bayer Corporation | Protein having proteinase inhibitor activity |
JP2003516755A (ja) * | 1999-12-15 | 2003-05-20 | ジェネンテック・インコーポレーテッド | ショットガン走査、すなわち機能性タンパク質エピトープをマッピングするための組み合わせ方法 |
JP2003534806A (ja) * | 2000-05-31 | 2003-11-25 | ジェンベク、インコーポレイティッド | アデノウイルスベクターのターゲティングの方法および組成物 |
US20020150594A1 (en) * | 2000-06-26 | 2002-10-17 | Maxygen, Inc. | Methods and compositions for developing spore display systems for medicinal and industrial applications |
EP1184393A1 (en) * | 2000-09-04 | 2002-03-06 | Debiopharm S.A. | Process for the purification of EPI-HNE proteins |
US6989438B2 (en) | 2000-09-04 | 2006-01-24 | Debiopharm S.A. | Process for the purification of EPI-HNE proteins |
KR100826342B1 (ko) | 2000-10-31 | 2008-05-02 | 데비오팜 에스 에이 | Epi-hne 단백질의 현탁액, 그의 제조 방법,그로부터 유도된 건조 분말 에어로졸, 상기 현탁액 또는에어로졸을 함유하는 제약학적 조성물 및 그의 용도 |
EP1201249A1 (en) * | 2000-10-31 | 2002-05-02 | Debiopharm S.A. | Suspension of EPI-HNE-4, dry powder aerosol derived therefrom, process of preparation thereof, pharmaceutical compositions containing said suspension or aerosol, and their uses |
US20050089932A1 (en) * | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
US20040175756A1 (en) * | 2001-04-26 | 2004-09-09 | Avidia Research Institute | Methods for using combinatorial libraries of monomer domains |
US20060223114A1 (en) * | 2001-04-26 | 2006-10-05 | Avidia Research Institute | Protein scaffolds and uses thereof |
US20050048512A1 (en) * | 2001-04-26 | 2005-03-03 | Avidia Research Institute | Combinatorial libraries of monomer domains |
AU2002256371B2 (en) * | 2001-04-26 | 2008-01-10 | Amgen Mountain View Inc. | Combinatorial libraries of monomer domains |
US20030157561A1 (en) * | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
US20050053973A1 (en) * | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
US20070160576A1 (en) | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
KR100576674B1 (ko) | 2001-06-20 | 2006-05-10 | 제넨테크, 인크. | 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물 |
US20030148408A1 (en) | 2001-09-18 | 2003-08-07 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US7803915B2 (en) | 2001-06-20 | 2010-09-28 | Genentech, Inc. | Antibody compositions for the diagnosis and treatment of tumor |
KR100801388B1 (ko) | 2002-01-02 | 2008-02-05 | 제넨테크, 인크. | 종양의 진단 및 치료 방법 및 이를 위한 조성물 |
WO2003062431A2 (en) * | 2002-01-23 | 2003-07-31 | Debiopharm Sa | Production of epi-hne-4 comprising reduction of improperly processed form |
US20050222023A1 (en) * | 2002-02-07 | 2005-10-06 | Hans-Peter Hauser | Albumin-fused kunitz domain peptides |
MXPA04010092A (es) | 2002-04-16 | 2004-12-13 | Genentech Inc | Composiciones y metodos para el diagnostico y tratamiento de tumores. |
EP2305710A3 (en) | 2002-06-03 | 2013-05-29 | Genentech, Inc. | Synthetic antibody phage libraries |
US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
CA2496925A1 (en) * | 2002-08-29 | 2004-03-11 | Genentech, Inc. | Achaete-scute like-2 polypeptides and encoding nucleic acids and methods for the diagnosis and treatment of tumor |
US6989369B2 (en) * | 2003-02-07 | 2006-01-24 | Dyax Corp. | Kunitz domain peptides |
PL1641822T3 (pl) | 2003-07-08 | 2013-10-31 | Genentech Inc | Heterologiczne polipeptydy IL-17 A/F i ich zastosowania terapeutyczne |
CA2537113A1 (en) * | 2003-08-29 | 2005-03-10 | Dyax Corp. | Modified protease inhibitors |
US20050164301A1 (en) * | 2003-10-24 | 2005-07-28 | Avidia Research Institute | LDL receptor class A and EGF domain monomers and multimers |
PT2161283E (pt) | 2003-11-17 | 2014-08-29 | Genentech Inc | Composições que compreendem anticorpos contra cd79b conjugados a um agente de inibição do crescimento ou agente citotóxico e métodos para o tratamento de tumor de origem hematopoiética |
WO2005094875A1 (en) * | 2004-03-31 | 2005-10-13 | Coloplast A/S | Use of epi-hne 1-4 |
AU2005250369A1 (en) * | 2004-05-18 | 2005-12-15 | Genentech, Inc. | M13 virus major coat protein variants for C-terminal and BI-terminal display of a heterologous protein |
EP1771212A1 (en) * | 2004-07-16 | 2007-04-11 | Coloplast A/S | A wound care device |
AU2005309722B2 (en) * | 2004-11-22 | 2011-10-20 | Dyax Corp. | Plasmin-inhibitory therapies |
WO2006091459A2 (en) * | 2005-02-24 | 2006-08-31 | Joslin Diabetes Center, Inc. | Compositions and methods for treating vascular permeability |
MX2007010922A (es) | 2005-03-10 | 2007-10-12 | Genentech Inc | Metodos y composiciones para modular la integridad vascular. |
JP2008541781A (ja) | 2005-06-06 | 2008-11-27 | ジェネンテック・インコーポレーテッド | 異なる遺伝子に対するトランスジェニック動物、および遺伝子の特徴づけのためのその使用 |
BRPI0614222A2 (pt) * | 2005-07-13 | 2011-03-15 | Amgen Mountain View Inc | proteìnas ligantes de il-6 |
WO2007021423A2 (en) | 2005-08-15 | 2007-02-22 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
GB0521404D0 (en) * | 2005-10-20 | 2005-11-30 | Ares Trading Sa | Kunitz domain containing protein |
WO2007081608A2 (en) | 2005-11-21 | 2007-07-19 | Genentech, Inc. | Novel gene disruptions, compositions and methods relating thereto |
KR101453570B1 (ko) | 2005-12-02 | 2014-10-22 | 제넨테크, 인크. | Il-22 및 il-22r에 결합하는 항체를 포함하는,사이토카인 신호 전달과 관련된 질환 및 장애 치료용조성물 및 치료 방법 |
US8993719B2 (en) | 2005-12-29 | 2015-03-31 | The Regents Of The University Of California | Methods and compositions related to mutant Kunitz domain I of TFPI-2 |
HUE038243T2 (hu) | 2005-12-29 | 2018-10-29 | Dyax Corp | Proteáz gátlás |
WO2007114979A2 (en) | 2006-02-17 | 2007-10-11 | Genentech, Inc. | Gene disruptons, compositions and methods relating thereto |
EP2614839A3 (en) | 2006-04-05 | 2015-01-28 | Genentech, Inc. | Method for using BOC/CDO to modulate hedgehog signaling |
CA2649387A1 (en) | 2006-04-19 | 2008-03-27 | Genentech, Inc. | Novel gene disruptions, compositions and methods relating thereto |
US20090142259A1 (en) * | 2006-05-12 | 2009-06-04 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors |
WO2008021290A2 (en) | 2006-08-09 | 2008-02-21 | Homestead Clinical Corporation | Organ-specific proteins and methods of their use |
ES2530438T3 (es) | 2006-09-12 | 2015-03-02 | Genentech Inc | Procedimientos y composiciones para el diagnóstico y tratamiento del cáncer de pulmón utilizando el gen de KIT o KDR como marcador genético |
US20100297103A1 (en) | 2006-09-14 | 2010-11-25 | Medical & Biological Laboratories Co., Ltd. | Antibody having enhanced adcc activity and method for production thereof |
WO2008091692A2 (en) * | 2007-01-25 | 2008-07-31 | Joslin Diabetes Center, Inc. | Methods of diagnosing, treating, and preventing increased vascular permeability |
US7875431B2 (en) | 2007-02-22 | 2011-01-25 | Genentech, Inc. | Methods for detecting inflammatory bowel disease |
EP2195010A4 (en) * | 2007-08-21 | 2012-03-14 | Genzyme Corp | TREATMENT WITH INHIBITORS OF KALLIKREINE |
JP5566293B2 (ja) * | 2007-10-04 | 2014-08-06 | バイオノミックス リミテッド | 内皮細胞マーカーおよびその使用 |
CN101186646B (zh) * | 2007-10-26 | 2010-06-09 | 中国科学院昆明动物研究所 | 眼镜王蛇毒蛋白酶抑制剂及其衍生物的应用 |
JP5985150B2 (ja) | 2007-11-07 | 2016-09-06 | ジェネンテック, インコーポレイテッド | 微生物障害の処置のための組成物および方法 |
CA2728473A1 (en) * | 2008-06-20 | 2009-12-23 | National University Corporation Okayama University | Antibody against oxidized ldl/.beta.2gpi complex and use of the same |
US9182406B2 (en) * | 2008-08-04 | 2015-11-10 | Biodesy, Inc. | Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability |
UA109108C2 (uk) | 2008-12-09 | 2015-07-27 | Дженентек, Інк. | Антитіло до pd-l1 та його застосування для посилення функції t-клітин |
US20110275535A1 (en) | 2008-12-16 | 2011-11-10 | Novartis Ag | Yeast Display Systems |
SI2379096T1 (sl) | 2008-12-19 | 2020-03-31 | Baxalta GmbH | Zaviralci TFPI in postopki uporabe |
EP2385843A4 (en) * | 2009-01-06 | 2013-02-27 | Dyax Corp | TREATMENT OF MUZOSITIS WITH CALLICINE INHIBITORS |
US8926976B2 (en) | 2009-09-25 | 2015-01-06 | Xoma Technology Ltd. | Modulators |
EP3187877A1 (en) | 2009-09-25 | 2017-07-05 | XOMA Technology Ltd. | Screening methods |
WO2011050194A1 (en) | 2009-10-22 | 2011-04-28 | Genentech, Inc. | Methods and compositions for modulating hepsin activation of macrophage-stimulating protein |
JP5856065B2 (ja) | 2009-11-30 | 2016-02-09 | ジェネンテック, インコーポレイテッド | 腫瘍の診断と治療のための組成物と方法 |
CA3168591A1 (en) | 2010-01-06 | 2011-07-14 | Takeda Pharmaceutical Company Limited | Plasma kallikrein binding proteins |
JP5981853B2 (ja) | 2010-02-18 | 2016-08-31 | ジェネンテック, インコーポレイテッド | ニューレグリンアンタゴニスト及び癌の治療におけるそれらの使用 |
JP5988436B2 (ja) | 2010-02-23 | 2016-09-07 | ジェネンテック, インコーポレイテッド | 腫瘍の診断と治療のための組成物と方法 |
WO2011115712A2 (en) | 2010-03-19 | 2011-09-22 | Baxter International Inc | Tfpi inhibitors and methods of use |
KR20130079384A (ko) | 2010-05-03 | 2013-07-10 | 제넨테크, 인크. | 종양의 진단 및 치료를 위한 조성물 및 방법 |
WO2012071436A1 (en) | 2010-11-24 | 2012-05-31 | Genentech, Inc. | Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants |
JP2014506257A (ja) | 2011-01-06 | 2014-03-13 | ダイアックス コーポレーション | 血漿カリクレイン結合タンパク質 |
CA2831136A1 (en) | 2011-03-21 | 2012-09-27 | Biodesy, Llc | Classification of kinase inhibitors using nonlinear optical techniques |
WO2012142526A1 (en) | 2011-04-14 | 2012-10-18 | Modiano Jaime | Use of tumor fas expression to determine response to anti-cancer therapy |
CA2843595C (en) | 2011-08-01 | 2022-10-18 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
JP2014533927A (ja) | 2011-09-15 | 2014-12-18 | ジェネンテック, インコーポレイテッド | 分化を促進する方法 |
CA2850836A1 (en) | 2011-10-15 | 2013-04-18 | Genentech, Inc. | Methods of using scd1 antagonists |
CN104168920A (zh) | 2012-01-18 | 2014-11-26 | 霍夫曼-拉罗奇有限公司 | 使用fgf19调控剂的方法 |
US20130209473A1 (en) | 2012-02-11 | 2013-08-15 | Genentech, Inc. | R-spondin translocations and methods using the same |
BR112014020173A8 (pt) | 2012-03-16 | 2017-07-11 | Hoffmann La Roche | Métodos para o tratamento de um melanoma, utilizações de um inibidor, composições, conjunto, método de inibição, método de identificação, método de ajuste do tratamento e invenção |
US9139863B2 (en) | 2012-03-16 | 2015-09-22 | Genentech, Inc. | Engineered conformationally-stabilized proteins |
WO2013137920A1 (en) | 2012-03-16 | 2013-09-19 | Genentech, Inc. | Engineered conformationally-stabilized proteins |
DK2827883T3 (da) | 2012-03-21 | 2019-07-29 | Baxalta GmbH | Tfpi-inhibitorer og fremgangsmåder til anvendelse |
EP2841951B1 (en) | 2012-04-25 | 2019-12-11 | Biodesy, Inc. | Methods for detecting allosteric modulators of proteins |
WO2013170191A1 (en) | 2012-05-11 | 2013-11-14 | Genentech, Inc. | Methods of using antagonists of nad biosynthesis from nicotinamide |
EP3556776A1 (en) | 2012-05-31 | 2019-10-23 | F. Hoffmann-La Roche AG | Methods of treating cancer using pd-1 axis binding antagonists and vegf antagonists |
EP2708235A1 (en) * | 2012-09-17 | 2014-03-19 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Peptide antagonists of the vasopressin-2 receptor |
WO2014128235A1 (en) | 2013-02-22 | 2014-08-28 | F. Hoffmann-La Roche Ag | Methods of treating cancer and preventing drug resistance |
RU2015137610A (ru) | 2013-03-06 | 2017-04-10 | Дженентек, Инк. | Способы лечения и профилактики лекарственной резистентности злокачественных опухолей |
KR20150127216A (ko) | 2013-03-14 | 2015-11-16 | 제넨테크, 인크. | 암의 치료 및 암 약물 내성의 예방 방법 |
KR102158924B1 (ko) | 2013-03-15 | 2020-09-22 | 제넨테크, 인크. | Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법 |
JP6456356B2 (ja) | 2013-03-15 | 2019-01-23 | ジェネンテック, インコーポレイテッド | IL−22ポリペプチド及びIL−22Fc融合タンパク質並びに使用方法 |
BR112015023203A8 (pt) | 2013-03-15 | 2018-01-23 | Constellation Pharmaceuticals Inc | métodos para tratamento de câncer, método para aumentar a eficiência de um tratamento de câncer, método para retardar e/ou prevenir o desenvolvimento de câncer, método para tratar um indivíduo com câncer, método para aumentar a sensibilidade para um agente de terapia para câncer, método para estender um período de sensibilidade e método para estender a duração da resposta para uma terapia para câncer. |
EP3021869B1 (en) | 2013-07-16 | 2020-07-15 | F. Hoffmann-La Roche AG | Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors |
US20150210772A1 (en) | 2013-12-17 | 2015-07-30 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody |
WO2015116902A1 (en) | 2014-01-31 | 2015-08-06 | Genentech, Inc. | G-protein coupled receptors in hedgehog signaling |
BR112016019390B1 (pt) * | 2014-02-24 | 2023-11-14 | Takeda Pharmaceutical Company Limited | Proteínas de fusão uti, composição farmacêutica compreendendo a referida proteína, ácido nucleico, vetor de expressão, célula hospedeira recombinante e método de produção de uma proteína de fusão uti |
EP3636073B1 (en) | 2014-05-05 | 2023-11-15 | Regeneron Pharmaceuticals, Inc. | Humanized c5 and c3 animals |
KR20170005016A (ko) | 2014-05-23 | 2017-01-11 | 제넨테크, 인크. | MiT 바이오마커 및 그의 사용 방법 |
US20230190750A1 (en) | 2014-06-13 | 2023-06-22 | Genentech, Inc. | Methods of treating and preventing cancer drug resistance |
CN114057857A (zh) | 2014-06-20 | 2022-02-18 | 豪夫迈·罗氏有限公司 | 基于chagasin的支架组合物、方法和应用 |
SG11201700074YA (en) | 2014-07-15 | 2017-02-27 | Genentech Inc | Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors |
WO2016037157A2 (en) | 2014-09-05 | 2016-03-10 | The Johns Hopkins University | Targeting capn9/capns2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies |
EP4141032B1 (en) | 2014-11-20 | 2024-05-29 | F. Hoffmann-La Roche AG | Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists |
US20160158360A1 (en) | 2014-12-05 | 2016-06-09 | Genentech, Inc. | Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists |
EP3237906B8 (en) | 2014-12-23 | 2020-10-28 | Bluelight Therapeutics, Inc. | Attachment of proteins to interfaces for use in nonlinear optical detection |
US10376535B2 (en) | 2015-03-26 | 2019-08-13 | University Of Rochester | Therapy for malignant disease |
JP6952605B2 (ja) | 2015-04-24 | 2021-10-20 | ジェネンテック, インコーポレイテッド | 多特異性抗原結合タンパク質 |
EP3718569B1 (en) | 2015-05-22 | 2023-05-03 | Translational Drug Development, LLC | Benzamide and active compound compositions and methods of use |
US20180188257A1 (en) | 2015-06-19 | 2018-07-05 | University Of Rochester | Septin proteins as novel biomarkers for detection and treatment of müllerian cancers |
WO2017058780A1 (en) | 2015-09-30 | 2017-04-06 | Merck Patent Gmbh | Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer |
US11273151B2 (en) | 2015-11-04 | 2022-03-15 | Icahn School Of Medicine At Mount Sinai | Methods of treating tumors and cancer, and identifying candidate subjects for such treatment |
EP3387018A1 (en) | 2015-12-11 | 2018-10-17 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
EP3405587A4 (en) | 2015-12-23 | 2019-10-30 | Moonshot Pharma LLC | METHOD FOR TRIGGERING AN IMMUNE REACTION THROUGH READ THROUGH PROMOTION OF A PREVIOUS TERMINATION CODON |
WO2017189730A1 (en) | 2016-04-26 | 2017-11-02 | Icahn School Of Medicine At Mount Sinai | Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment |
US11292801B2 (en) | 2016-07-05 | 2022-04-05 | Blade Therapeutics, Inc. | Calpain modulators and therapeutic uses thereof |
WO2018049275A1 (en) | 2016-09-09 | 2018-03-15 | Genentech, Inc. | Selective peptide inhibitors of frizzled |
CA3038331A1 (en) | 2016-09-28 | 2018-04-05 | Blade Therapeutics, Inc. | Calpain modulators and therapeutic uses thereof |
IL300095A (en) | 2016-11-23 | 2023-03-01 | Translational Drug Dev Llc | Compositions of benzamide and an agonist for the cancer necrosis factor receptor superfamily and uses thereof |
WO2018152496A1 (en) | 2017-02-17 | 2018-08-23 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Compositions and methods for the diagnosis and treatment of zika virus infection |
US10765762B2 (en) | 2017-02-27 | 2020-09-08 | Regeneron Pharmaceuticals, Inc. | Humanized model of kidney and liver disorders |
US20190078160A1 (en) | 2017-04-21 | 2019-03-14 | Genentech, Inc. | Use of klk5 antagonists for treatment of a disease |
US11236151B2 (en) | 2017-04-25 | 2022-02-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection |
US11654135B2 (en) | 2017-06-22 | 2023-05-23 | Moonshot Pharma Llc | Methods for treating colon cancer with compositions comprising amlexanox and immune checkpoint inhibitors |
CN111094334A (zh) | 2017-07-19 | 2020-05-01 | 美国卫生与公众服务部 | 用于诊断和治疗乙肝病毒感染的抗体和方法 |
WO2019126472A1 (en) | 2017-12-22 | 2019-06-27 | Genentech, Inc. | Use of pilra binding agents for treatment of a disease |
US11427932B2 (en) * | 2019-04-17 | 2022-08-30 | Impossible Foods Inc. | Materials and methods for protein production |
WO2020227554A1 (en) | 2019-05-09 | 2020-11-12 | Genentech, Inc. | Methods of making antibodies |
JP2022534889A (ja) | 2019-05-24 | 2022-08-04 | ファイザー・インコーポレイテッド | Cdk阻害剤を使用した組合せ療法 |
CN115515616A (zh) | 2020-03-05 | 2022-12-23 | 代阿麦迪卡美国股份有限公司 | 乌司他丁多肽 |
US20210338833A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Chimeric antigen receptor-targeting ligands and uses thereof |
US20210340524A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof |
CN116685325A (zh) | 2020-10-20 | 2023-09-01 | 豪夫迈·罗氏有限公司 | Pd-1轴结合拮抗剂和lrrk2抑制剂的组合疗法 |
US20220168293A1 (en) | 2020-12-02 | 2022-06-02 | Pfizer Inc. | Time to resolution of axitinib-related adverse events |
CN112940095B (zh) * | 2021-02-07 | 2022-04-15 | 西南大学 | 家蚕BmSPI51突变蛋白BmSPI51M及其制备方法和应用 |
BR112023025738A2 (pt) | 2021-06-09 | 2024-02-27 | Hoffmann La Roche | Combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, uso de uma combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, método para o tratamento ou profilaxia de câncer, composição farmacêutica e invenção |
WO2023057882A1 (en) | 2021-10-05 | 2023-04-13 | Pfizer Inc. | Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0401508T3 (da) * | 1989-05-13 | 1995-05-15 | Bayer Ag | Proteaseinhibitorer, fremgangsmåde til deres fremstilling samt lægemidler med indhold deraf |
US5409895A (en) * | 1990-11-13 | 1995-04-25 | Mochida Pharmaceutical Co., Ltd. | Protease inhibitory polypeptides derived from urinary trypsin inhibitor and compositions thereof |
CA2105304C (en) * | 1991-03-01 | 2005-10-04 | Arthur C. Ley | Inhibitors of human neutrophil elastase and human cathepsin g |
AU3061092A (en) * | 1991-10-31 | 1993-06-07 | Salk Institute Biotechnology/Industrial Associates, Inc., The | Recombinant amyloid precursor protein inhibitor domain and treatment of various disease states |
IL104314A0 (en) * | 1992-01-07 | 1993-05-13 | Novo Nordisk As | Human kunitz-type protease inhibitor and variants thereof,their production and pharmaceutical compositions containing them |
JP2769083B2 (ja) * | 1993-02-22 | 1998-06-25 | 日清食品株式会社 | エラスターゼ阻害活性を有する新規ペプチドおよびその製造方法 |
JP3570558B2 (ja) * | 1993-05-01 | 2004-09-29 | 持田製薬株式会社 | Dna断片およびそれを含むベクター、該ベクターによって形質転換された形質転換体、該ベクターを用いる蛋白質の産生方法 |
DE69533544T2 (de) * | 1994-01-11 | 2006-02-23 | Dyax Corp., Cambridge | Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten |
CA2220497A1 (en) * | 1995-05-08 | 1996-11-14 | Scios, Inc. | Kunitz type protease inhibitors |
-
1994
- 1994-12-16 US US08/358,160 patent/US5663143A/en not_active Expired - Lifetime
-
1995
- 1995-12-15 JP JP52049196A patent/JP3977419B2/ja not_active Expired - Lifetime
- 1995-12-15 WO PCT/US1995/016349 patent/WO1996020278A2/en active IP Right Grant
- 1995-12-15 DK DK95943819T patent/DK0797666T3/da active
- 1995-12-15 EP EP05025964A patent/EP1734121A3/en not_active Withdrawn
- 1995-12-15 DE DE69534656T patent/DE69534656T2/de not_active Expired - Lifetime
- 1995-12-15 ES ES95943819T patent/ES2255066T3/es not_active Expired - Lifetime
- 1995-12-15 EP EP95943819A patent/EP0797666B1/en not_active Expired - Lifetime
- 1995-12-15 CA CA002207820A patent/CA2207820A1/en not_active Abandoned
- 1995-12-15 AT AT95943819T patent/ATE311452T1/de not_active IP Right Cessation
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005538932A (ja) * | 2002-02-07 | 2005-12-22 | アベンティス、ベーリング、ゲゼルシャフト、ミット、ベシュレンクテル、ハフツング | アルブミン融合クニッツドメインペプチド |
US9480733B2 (en) | 2002-06-07 | 2016-11-01 | Dyax Corp. | Prevention and reduction of blood loss |
US10245307B2 (en) | 2002-06-07 | 2019-04-02 | Dyax Corp. | Prevention and reduction of blood loss |
US11344610B2 (en) | 2002-06-07 | 2022-05-31 | Takeda Pharmaceutical Company Limited | Prevention and reduction of blood loss |
JP2010254708A (ja) * | 2003-08-29 | 2010-11-11 | Dyax Corp | ポリペグ化されたプロテアーゼインヒビター |
JP2011231115A (ja) * | 2003-08-29 | 2011-11-17 | Dyax Corp | ポリペグ化されたプロテアーゼインヒビター |
JP2014129391A (ja) * | 2003-08-29 | 2014-07-10 | Dyax Corp | ポリペグ化されたプロテアーゼインヒビター |
US9757437B2 (en) | 2004-09-27 | 2017-09-12 | Dyax Corp. | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
US10428158B2 (en) | 2014-03-27 | 2019-10-01 | Dyax Corp. | Compositions and methods for treatment of diabetic macular edema |
US11046785B2 (en) | 2014-03-27 | 2021-06-29 | Takeda Pharmaceutical Company Limited | Compositions and methods for treatment of diabetic macular edema |
Also Published As
Publication number | Publication date |
---|---|
ATE311452T1 (de) | 2005-12-15 |
ES2255066T3 (es) | 2006-06-16 |
DE69534656T2 (de) | 2006-08-17 |
CA2207820A1 (en) | 1996-07-04 |
EP0797666A2 (en) | 1997-10-01 |
JP3977419B2 (ja) | 2007-09-19 |
DK0797666T3 (da) | 2006-04-03 |
EP1734121A3 (en) | 2008-09-10 |
EP1734121A2 (en) | 2006-12-20 |
WO1996020278A3 (en) | 1996-10-24 |
DE69534656D1 (de) | 2006-01-05 |
EP0797666B1 (en) | 2005-11-30 |
US5663143A (en) | 1997-09-02 |
WO1996020278A2 (en) | 1996-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3977419B2 (ja) | ヒト好中球エラスターゼ阻害特別設計ヒト由来クニッツドメイン | |
Neeper et al. | Characterization of recombinant tick anticoagulant peptide. A highly selective inhibitor of blood coagulation factor Xa. | |
EP0339942B1 (en) | Aprotinin analogues and process for the production thereof | |
EP0139383A1 (en) | Method for expressing foreign genes in schizosaccharomyces pombe and the use in therapeutic formulations of the products, DNA constructs and transformant strains of schizosaccharomyces pombe usable in such method and their preparation | |
PT94016B (pt) | Processo para a producao de inibidores de proteinases | |
EP0402068B1 (en) | Polypeptides and polypeptide analogues with inhibitory activity against human elastase | |
US5378614A (en) | Vector and method for making tissue factor pathway inhibitor (TFPI) analogues in yeast | |
US5278285A (en) | Variant of Kunitz-type inhibitor derived from the α3-chain of human type VI collagen produced by recombinant DNA technology | |
Pohlig et al. | Purification, Characterization and Biological Evaluation of Recombinant Leech‐Derived Tryptase Inhibitor (rLDTI) Expressed at High Level in the Yeast Saccharomyces Cerevisiae | |
CA2025070C (en) | Recombinant aprotinin variants genetically engineered process for the microbial preparation of homgeneously processed aprotinin variants and the therapeutic use thereof | |
CZ285225B6 (cs) | Aprotininová analoga | |
Bourbonnais et al. | Production of full-length human pre-elafin, an elastase specific inhibitor, from yeast requires the absence of a functional yapsin 1 (Yps1p) endoprotease | |
Morishita et al. | Novel factor Xa and plasma kallikrein inhibitory-activities of the second Kunitz-type inhibitory domain of urinary trypsin inhibitor | |
AU661515B2 (en) | Polypeptide, DNA fragment encoding the same, drug composition containing the same and process for producing the same | |
US5266465A (en) | α-1-antichymotrypsin, analogues and methods of production | |
US20060269536A1 (en) | Inhibitor proteins of a protease and use thereof | |
DE19629982A1 (de) | Aprotinin-Varianten mit verbesserten Eigenschaften | |
EP0261080B1 (en) | Recombinant ligninase | |
Auerswald et al. | Production, inhibitory activity, folding and conformational analysis of an N‐terminal and an internal deletion variant of chicken cystatin | |
AU2007222621A1 (en) | Chimeric Kunitz domains and their use | |
JP2798573B2 (ja) | ヒト好中球エラスターゼ阻害活性を有する天然型ポリペプチドおよびそれを含有する医薬製剤 | |
US5231010A (en) | Recombinant aprotinin variants genetically engineered process for the microbial preparation of homogeneously processed aprotinin variants and the therapeutic use thereof | |
EP1002083A1 (de) | Aprotininvarianten mit verbesserten eigenschaften und bikunine von aprotininvarianten | |
WO2009030464A2 (de) | HERSTELLUNG UND VERWENDUNG VON VARIANTEN HUMANER KUNITZ-TYP PROTEASE-INHIBITOREN (hKTPI) | |
Campbell | Protein engineering of the barley chymotrypsin inhibitor 2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060131 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060427 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20061024 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070129 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20070315 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070416 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070511 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070530 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070621 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100629 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |